Tobias Kanacher, Ph.D.

Senior Consultant

Portrait-of-Tobias-Kanacher-Pharmetheus

Bio

  • Joined Pharmetheus in 2019, actively working in client projects
  • Expertise includes physiological based pharmacokinetic modeling (PBPK), pediatrics, and MIDD in therapeutic areas such as oncology, women’s health, and cardiovascular diseases
  • Previously worked as Consultant Modeling and Simulation at SGS Exprimo NV, Belgium, where he provided advice and hands-on application of pharmacometric approaches to support drug development in various therapeutic areas, as Systems Pharmacology Expert at Bayer / Bayer Technology Services GmbH, Germany, PBPK Expert in Exploratory ADME at Nycomed: a Takeda Company, Germany, Laboratory Team Leader in Exploratory ADME at Altana Pharma AG / Nycomed Gmbh, Germany, and Laboratory Team and Target-Project Leader in Preclinical Research at Altana Pharma AG, Germany
  • Pharmacist Licensure (1999) from the University Marburg, Germany, and Ph.D. in Pharmaceutical Biochemistry (2003) from the University Tübingen, Germany
LinkedInGoogle Scholar

Pharmetheus affiliated publications

Assessing Drug–Drug Interaction and Food Effect for BCS Class 2 Compound BI 730357 (Retinoic Acid-Related Orphan Receptor Gamma Antagonist, Bevurogant) Using a Physiology-Based Pharmacokinetics Modeling (PBPK) Approach with Semi-Mechanistic AbsorptionA Physiologically Based Pharmacokinetic Model of Atorvastatin Acid Predicting CYP3A4 and OATP1B Drug–Drug InteractionsDevelopment of a Physiologically-Based Pharmacokinetic Model for Coproporphyrin I (CP-I) Using the Open Systems Pharmacology Software Suite (PK-Sim and MoBi) for assessment of OATP1B-based DDIsA Physiologically-Based Pharmacokinetic (PBPK) Model Network for the Prediction of CYP1A2 and CYP2C19 Drug-Drug-Gene Interactions with Fluvoxamine, Omeprazole, S-mephenytoin, Moclobemide, Tizanidine, Mexiletine, Ethinylestradiol, and Caffeine [1]